The verdict
Our read at a glance.
Whether a synthetic amphetamine-adjacent stimulant becomes a dietary ingredient by being attributed to a plant.
- The signal
- The scientific record is unusually decisive on the central question. Multiple analytical studies examined whether DMAA occurs naturally in geranium, and the weight of that work concluded it does not occur at meaningful levels - the material in supplements was synthetic. Pharmacology work characterised it as an alkylamine stimulant with substrate-like activity at monoamine transporters, and its abuse liability has been assessed directly. Analytical surveys of sports and weight-loss supplements repeatedly found it alongside other prohibited experimental stimulants, and a recreational-use literature describes the pattern. Reported harms include hypertension, cardiac arrest, cerebral haemorrhage and deaths, several in military personnel, which is what triggered the regulatory response.
- The unknown
- Nothing about the compound. The unresolved problem is structural: the same loophole keeps producing successors, and the analytical literature already documents a queue of them.
- Our read
- The founding case study for the botanical-name loophole. A synthetic stimulant was attributed to a plant to make it a supplement ingredient, the chemistry said otherwise, and people died before it was removed. Every subsequent stimulant sold under a botanical name should be read against this page.
The mechanism
How it works.
DMAA is an aliphatic amine structurally related to amphetamine, with the aromatic ring replaced by a branched alkyl chain. It acts as an indirect sympathomimetic: rather than binding adrenergic receptors itself, it interacts with monoamine transporters in a substrate-like way, promoting release of noradrenaline and blocking its reuptake. Raised synaptic noradrenaline produces the alertness, focus and perceived energy people take it for, and simultaneously produces vasoconstriction, a rise in systemic blood pressure and increased cardiac workload. The reason the harm reports cluster around exercise is that this pharmacology stacks with what training already does to blood pressure and heart rate, and the products were usually taken immediately before intense exertion, often with caffeine, which acts on a converging pathway.
Safety & regulatory boundary
The consequential part.
FDA has stated DMAA is not a lawful dietary ingredient and has taken enforcement action, including seizures, and it is banned in numerous other countries. Prohibited in sport. It raises blood pressure and heart rate substantially and has been associated with cardiac and cerebrovascular events, with risk amplified by exercise, heat and combination with other stimulants - which is exactly the context a pre-workout is used in.
What's next
What we're watching.
The next generation of substituted alkylamines appearing under botanical names, which the surveillance literature is already tracking.
Context
Why this is discussed.
It defined the pre-workout category, the stimulant effect was genuinely strong, and its removal is still described in the industry as regulatory overreach.
The evidence base
11 cited references.
Indexed literature (PubMed)11
Zhang Y et al. · Drug Test Anal · 2012
Van Hout MC et al. · Int J Drug Policy · 2015
Cohen PA et al. · Clin Toxicol (Phila) · 2021
Small C et al. · J Pharmacol Exp Ther · 2023
Dunn M · Int J Drug Policy · 2017
Cohen PA et al. · Clin Toxicol (Phila) · 2018
Dolan SB et al. · Drug Alcohol Depend · 2015
Di Lorenzo C et al. · Drug Test Anal · 2013
Gauthier TD · Anal Chem Insights · 2013
Monakhova YB et al. · Drug Test Anal · 2014
Cohen PA · Arch Intern Med · 2012
Keep reading